Please assess the completion status of the following clinical trial:

Trial Title: In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a documented clinical diagnosis of grade II-IV acute graft-versus- host disease defined as graft versus host disease (GVHD) occurring within the first 100 days of transplantation~* Patients must be steroid-refractory defines as progression after 3 days of corticosteroid therapy or no response after 5 days of corticosteroid therapy.~* Progression is defined as up-grading~* No response is defined as no down-grading~* Progression after 3 days requires patients to have received at least 2 mg/mg/day for a total of 6 mg/kg of methylprednisolone or its equivalent.~* No response after 5 days requires patient to have received at least 2 mg/kg/d for a total of 10 mg/kg of methylprednisolone or its equivalent.~* Patients with exacerbation of GVHD during steroid taper will require re-treatment with 2mg/kg/d of corticosteroids and will need to meet the criteria~* Age 18-70~* Patients must have received an allogeneic hematopoietic stem cell transplant within 100 days of study enrollment.~* Serum creatinine \< 2 mg/dL~Exclusion Criteria:~* Patients cannot have active central nervous system (CNS) disease.~* Patients must not have received cyclophosphamide for GVHD prophylaxis~* Patients must not have pneumonia requiring oxygen supplementation~* Unable or unwilling to sign informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide and Sirolimus (Type: EXPERIMENTAL): cyclophosphamide and sirolimus combo
- Lowdose IL-2, Cytoxan + Sirolimus (Type: EXPERIMENTAL): Low dose IL-2 with Cytoxan + Sirolimus Patients in treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus.
- Lowdose IL-2, Vidaza, cyclophosphamide & Sirolimus (Type: EXPERIMENTAL): Lowdose IL-2, Vidaza, cyclophosphamide (Cytoxan) \& Sirolimus Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza).

Based on this trial design, predict the completion outcome and termination type (if applicable).